Echo-encephalographic study of ventricular dilatation after subarachnoid hemorrhage, with special reference to the effect of antifibrinolytic treatment.
Echo-encephalographic examinations were performed in 144 patients after subarachnoid hemorrhage. Ninety-three of the patients received antifibrinolytic treatment (AMCA). The width of the third ventricle could be measured in all the patients, and lateral ventricle measurements were obtained in 94 patients. Third ventricular dilatation developed in 78 patients (54 per cent), and lateral ventricle enlargement was seen in 55 patients (58 per cent of those examined). The incidence of third ventricle dilatation was higher in the AMCA-treated group (62.5 per cent) than in the non-treated group (39.2 per cent), and this difference was statistically significant (P less than 0.05). The hydrocephalus in most cases developed 2-3 weeks after the bleeding, and reached its peak within the first 2-3 months, with subsequent complete or partial normalization of the ventricular size. At later follow-up examinations 1-4 years after the bleeding, only nine patients had persisting dilatation of moderate or pronounced degree. There was no indication that the dilatation was more severe or pronounced degree. There was no indication that the dilatation was more severe or protracted in the AMCA-treated group than in the non-treated group. In 11 patients the hydrocephalus required a shunt-operation, but the frequency of shunt-operations was not significantly different in the two groups. It is concluded that although AMCA-treated patients in comparison with non-treated patients are exposed to a somewhat higher risk of complicating hydrocephalus after subarachnoid hemorrhage, this risk cannot at present be considered as any serious contraindiction to this sort of treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002552:Cerebral Ventricles / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004106:Dilatation; D004453:Echoencephalography; D006801:Humans; D008875:Middle Aged; D013345:Subarachnoid Hemorrhage / Q000175:diagnosis* / Q000188:drug therapy; D014148:Tranexamic Acid / Q000494:pharmacology / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid